CBD is widely sold, but clinical use still lags behind
Regulation and Use of Cannabidiol in Croatia Compared with Selected European and International Models: From Consumer Products to Clinical Practice.
AI Summary
This narrative review compares how cannabidiol (CBD) is regulated, sold, and used in Croatia, selected European Union countries, Canada, and Australia. It finds substantial differences in product rules, access to medical cannabis, reimbursement, clinical use, and the involvement of pharmacists. Germany and the Netherlands have more developed systems for medical cannabis, while Finland follows a more restrictive approach.
In Croatia, CBD-containing products are widely available to consumers, but their use in routine healthcare remains limited. The review identifies regulatory uncertainty, limited professional training, and a lack of standardised clinical guidance as important barriers. Overall, the consumer market has expanded faster than the integration of cannabinoid-based treatments into healthcare, suggesting that clearer guidance and better training are needed for evidence-based use.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.